CurrentCignaPolicy IP0327

Human Chorionic Gonadotropin (hCG) Injection — Non‑Fertility Indications

Defines medical necessity criteria and coverage for urine-derived human chorionic gonadotropin products (Novarel, Pregnyl, chorionic gonadotropin injection) for non‑fertility indications under Cigna benefit plans.

Policy Summary

PayerCigna

PolicyHuman Chorionic Gonadotropin (hCG) Injection — Non‑Fertility Indications

Policy CodePolicy IP0327

Change TypeNo material changes

Effective DateFeb 15, 2024

Next Review DateFeb 15, 2025

Key ActionObtain prior authorization; initial approvals up to 6 months for prepubertal cryptorchidism and one-time authorization for diagnostic testosterone stimulation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1covered indications required

6initial approval (months)

one-timediagnostic authorization

J0725HCPCS code

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Covered Indications (non‑fertility)

Human chorionic gonadotropin (Novarel, Pregnyl, chorionic gonadotropin) is considered medically necessary when ONE of the following is met:

Medically necessary indications: 1) Treatment of prepubertal cryptorchidism. Individual meets ALL of the following criteria: A. Between the ages of 4 to 9 years old; B. Documented diagnosis of prepubertal cryptorchidism not due to anatomical obstruction.

Diagnostic use: 2) Diagnostic testosterone stimulation test. Individual meets ALL of the following criteria: A. Human chorionic gonadotropin (hCG) is to be used for evaluation of suspected hypogonadism in a pediatric individual; B. Medication is prescribed by a provider who specializes in pediatric endocrinology or pediatric urology.

inv-02: Continuation / Reauthorization

Reauthorization criteria and durations:

Reauthorization for prepubertal cryptorchidism: Continuation is considered medically necessary when the initial medical necessity criteria are met AND there is documentation of beneficial response.

Initial and reauthorization approval duration: up to 6 months each.

Diagnostic test continuation: Diagnostic testosterone stimulation test: Not applicable for continuation beyond initial one-time approval.

Authorization: one-time for diagnostic purposes.

Any use of human chorionic gonadotropin (hCG) that is not listed as a covered indication in this policy is considered experimental, investigational, or unproven. Examples of such excluded uses include, but are not limited to: use for obesity, concurrent use or combination with testosterone therapy, management of sexual dysfunction (including erectile dysfunction), treatment of low testosterone when hypogonadotropic hypogonadism is not present, and treatment of low testosterone concurrently with testosterone therapy.

Use of hCG for obesity and weight loss is not supported by evidence and is considered not medically necessary / experimental for this indication. The prescribing information for Novarel and Pregnyl states hCG has not been demonstrated to be an effective adjunctive therapy for obesity, and systematic reviews and meta-analyses do not show hCG provides weight loss or favorable fat redistribution beyond caloric restriction.

Coding

Considered Medically Necessary HCPCS CodesHCPCSCovered

J0725

Injection, chorionic gonadotropin, per 1,000 USP units

Age for prepubertal cryptorchidism

Age range4-9 years

Condition specifiedPrepubertal cryptorchidism (not due to anatomical obstruction)

Context for useAge range applies to pediatric patients being considered for hCG therapy to induce testicular descent

Provider Actions & Requirements

Prior Authorization

Prior Authorization & Approval Duration

Prior authorization is required. Initial approval: up to 6 months for treatment of prepubertal cryptorchidism. Diagnostic testosterone stimulation test: one-time authorization for diagnostic testing purposes.

Initial approval duration: up to 6 months for prepubertal cryptorchidism
Diagnostic testosterone stimulation test: one-time authorization

Note

Provider Requirements

Provider must follow prior authorization requirements and submit clinical documentation that supports the requested indication and duration. Ensure prescriptions for diagnostic hCG testing are ordered by a pediatric endocrinologist or pediatric urologist when applicable.

Documentation Required

Documentation Required for Reauthorization

For continuation (reauthorization) of hCG for prepubertal cryptorchidism, documentation of beneficial response is required. Diagnostic testosterone stimulation testing is not eligible for continuation beyond the initial one-time approval; no reauthorization is applicable for diagnostic testing.

Reauthorization approval duration: up to 6 months for continued treatment when benefit is documented
Diagnostic testosterone stimulation test: Not applicable for continuation

Denial Risk

Excluded Uses / Denial Risks

Any use not listed as medically necessary may be denied. Examples of excluded or not covered uses include, but are not limited to: obesity; use in combination with testosterone therapy; sexual dysfunction (including erectile dysfunction); treatment of low testosterone absent hypogonadotropic hypogonadism; and treatment of low testosterone due to hypogonadotropic hypogonadism concurrently with testosterone therapy.

Obesity
Use in combination with testosterone therapy
Sexual dysfunction, including erectile dysfunction
Treatment of low testosterone without hypogonadotropic hypogonadism
Treatment of low testosterone due to hypogonadotropic hypogonadism concurrently with testosterone therapy

Initial Therapy and Dosing

inv-13: Initial therapy and dosing reference

Dosing regimens and durations referenced in labeling; initial approval durations provided by policy.

Initial approval duration: Prepubertal cryptorchidism: initial approval up to 6 months; Diagnostic testosterone stimulation test: one-time authorization.

Dosing options per product labeling (examples from Table 1): 4,000 USP units three times weekly for 3 weeks; 5,000 USP units every second day for 4 injections; 15 injections of 500–1,000 USP units over 6 weeks; 500 USP units three times weekly for 4–6 weeks (if unsuccessful, repeat series with 1,000 USP units). For select hypogonadotropic hypogonadism regimens and ovulation induction regimens, see product labeling.

Continuation Criteria

inv-14: Continuation for prepubertal cryptorchidism

Continuation rules for prepubertal cryptorchidism

Continuation: Medical necessity criteria must continue to be met AND documentation of beneficial response is required.

Reauthorization approval duration: up to 6 months.

Age range: Patient age should be within the policy-specified prepubertal range (4 to 9 years).4-9 years

Step	Requirement
Step 0	No step therapy requirements specified in this policy.

Background

Human chorionic gonadotropin (hCG) is a urine-derived gonadotropin with activity similar to luteinizing hormone that stimulates gonadal steroid production. In males, hCG stimulates androgen production and can be used to induce testicular androgenization or to evaluate testicular function. hCG is available as branded products (e.g., Novarel, Pregnyl) and as generic chorionic gonadotropin formulations for intramuscular injection.

Definitions

hCG (human chorionic gonadotropin)

DefinitionA urine-derived gonadotropin with LH-like activity that stimulates gonadal steroid production

Available product namesNovarel, Pregnyl, chorionic gonadotropin (urine-derived)

Formulation and routeUrine-derived intramuscular injection (IM only)

Typical vial sizesPregnyl: 10,000 USP units; Novarel: 5,000 and 10,000 USP units; generic chorionic gonadotropin: 10,000 USP units